Topic: idiopathic pulmonary fibrosis
The deal comes one year after Galapagos landed global rights to an early-stage idiopathic pulmonary fibrosis treatment in development at Fibrocor.
Boehringer is swallowing Enleofen’s anti-IL-11 antibody platform, putting it on the hook for up to $1 billion in milestones per product.
Darren Kelly, Ph.D., CEO of fibrosis-focused companies Certa Therapeutics and OccuRx, discusses his many jobs and the need for few fibrosis drugs.
Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.
Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.
Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.
Samumed CEO Osman Kibar discusses regenerative medicine, drugging the Wnt pathway and his company's unorthodox journey.
Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.
The deal gives Gilead access to all of Galapagos’ current and future programs outside of Europe.
Lung Therapeutics has raised a $36 million series C round to take a treatment for a serious complication of pneumonia through phase 2 studies.